Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02917798 |
Recruitment Status :
Recruiting
First Posted : September 28, 2016
Last Update Posted : October 4, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Ovarian Cancer Prostate Cancer Pancreas Cancer | Behavioral: Assessments |
Study Type : | Observational |
Estimated Enrollment : | 1022 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes |
Actual Study Start Date : | July 12, 2016 |
Estimated Primary Completion Date : | September 2025 |
Estimated Study Completion Date : | September 2025 |
Group/Cohort | Intervention/treatment |
---|---|
Genetic Testing in Ovarian ,Prostate or Pancreas Cancer
This study is a prospective single-arm study to examine how an alternative clinical genetics cancer care delivery model affects ovarian, prostate or pancreas cancer patients' cognitions, emotions, and behaviors. Participants will be contacted 1 week (+/- 1 week) (Assessment #2; and 3 months (+/- 2 weeks) (Assessment #3;) following the telephone post-test counseling session to complete the follow-up assessments. These assessments will measure psychological and behavioral study constructs.
|
Behavioral: Assessments |
- baseline to post-results change in distress levels [ Time Frame: 2 years ]Change in distress levels (HADS-Anxiety) from Baseline to Assessments #2 and #3, measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- MSK patient age 18 years or older.
- Diagnosed with or presumed by physician to have prostate cancer, or pancreatic cancer and recommended to undergo, currently undergoing, or having undergone active surveillance. (Patients with invasive epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer, or pancreas cancer are no longer eligible for inclusion as of Amendment 9. Patients with advanced prostate cancer who have not participated in active surveillance are no longer eligible for inclusion as of Amendment 10)
- Deemed to be clinically appropriate for multiplex genetic testing by their physician.
- Agreed to receive clinical multiplex genetic testing from their physician.
- English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.
Exclusion Criteria:
- Patients who do not or will not receive their ongoing cancer care at MSK.
- Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation.
- Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.
- For ovarian cancer patients only: patient insured by a payer that does not provide coverage for multiplex genetic testing as delivered in this protocol (e.g., Cigna, United Health Care, or Oxford, (because these payers require genetic counseling by a genetics professional prior to testing).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02917798
Contact: Maria Carlo, MD | 646-422-4438 | carlom@mskcc.org | |
Contact: Mark Robson, MD | 646-888-4058 |
United States, New Jersey | |
Memorial Sloan Kettering Basking Ridge | Recruiting |
Basking Ridge, New Jersey, United States | |
Contact: Maria Carlo, MD 646-422-4438 | |
Principal Investigator: Maria Carlo, MD | |
United States, New York | |
Memorial Sloan Kettering Commack | Recruiting |
Commack, New York, United States, 11725 | |
Contact: Maria Carlo, MD 646-422-4438 | |
Principal Investigator: Maria Carlo, MD | |
Memorial Sloan Kettering Westchester | Recruiting |
Harrison, New York, United States, 10604 | |
Contact: Maria Carlo, MD 646-422-4438 | |
Memorial Sloan Kettering Cancer Center | Recruiting |
New York, New York, United States, 10065 | |
Contact: Maria Carlo, MD 646-422-4438 | |
Principal Investigator: Maria Carlo, MD | |
Memorial Sloan Kettering Rockville Centre | Recruiting |
Rockville Centre, New York, United States | |
Contact: Maria Carlo, MD 646-422-4438 |
Principal Investigator: | Maria Carlo, MD | Memorial Sloan Kettering Cancer Center |
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT02917798 |
Other Study ID Numbers: |
16-919 |
First Posted: | September 28, 2016 Key Record Dates |
Last Update Posted: | October 4, 2023 |
Last Verified: | October 2023 |
Genetic Testing 16-919 |
Pancreatic Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms |
Endocrine System Diseases Digestive System Neoplasms Digestive System Diseases Pancreatic Diseases |